Updates in Philadelphia-positive acute lymphoblastic leukemia treatment are highlighted following ASCO 2023.
EP. 1: Defining and Diagnosing Philadelphia Chromosome-Positive (Ph+) ALL
Amanda Przespolewski, DO, and Ibrahim Aldoss, MD define and discuss how to diagnose patients with Ph+ALL.
EP. 2: Evolving Standard of Care for Patients Diagnosed with Ph+ ALL
Drs Aldoss and Przespolewski evaluate the changing treatment landscape for patients diagnosed with Ph+ ALL.
EP. 3: Recent Updates from the PhALLCON Study
Medical experts highlight recent findings from the PhALLCON study.
EP. 4: Ponatinib and Blinatumomab Use in Patients with Newly Diagnosed Ph+ ALL
Dr Aldoss discusses the role ponatinib and blinatumomab in the management of Ph+ALL.
EP. 5: Notable Advancements in Treatment for ALL
Key advances in ALL treatment from ASCO 2023 are discussed by Dr Przespolewski.
EP. 6: Unmet Needs and Treatment Trajectory for Patients Diagnosed with Ph+ ALL
With their final thoughts, medical experts share unmet needs in the treatment landscape of Ph+ acute lymphoblastic leukemia.
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management
Five Under 5: Top Oncology Videos for the Week of 2/16
Darolutamide With ADT/Docetaxel Shows Reduced Risk of Death in mHSPC Irrespective of Age
Real-World Analysis Reveals Gaps in HRR Testing and PARP Inhibitor Treatment in mCRPC
Strategic and Safe Lorlatinib Use Is Key to Optimal ALK+ NSCLC Management